PTPN11 and myeloproliferative disorder: In a KITD814V-driven MPD model, SHP2 KO impaired transformation of bone marrow progenitors, and a small molecule inhibitor of SHP2 (II-B08) [30] was shown to synergize with a PI3K inhibitor to repress mast cell leukemia in MPD mice [31].